Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
September 04, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
July 19, 2024 08:29 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
March 11, 2024 08:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
October 30, 2023 08:30 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
October 19, 2023 16:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.
Former United Executive Confirms Dan Rosenthal’s Involvement in Yale Study
November 09, 2021 14:00 ET
|
TeamHealth
LAS VEGAS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The Las Vegas trial between health insurance giant United and TeamHealth Nevada emergency room clinicians entered its third week yesterday, with Judge...
Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics
May 10, 2021 08:30 ET
|
Gennao Bio
~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...
CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University
August 13, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered...
American Health Council Names Si-Hoi Lam, M.D. to Education Board
May 19, 2017 08:00 ET
|
American Health Council
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Dr. Si-Hoi Lam, Assistant Clinical Professor at Yale University School of Medicine, has been selected to join the Education Board at the American Health...